ADT1031-Anatumomab Mafenatox Biosimilar-Anti-TAG-72 mAb-Research Grade
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1031 |
Product Name |
ADT1031-Anatumomab Mafenatox Biosimilar-Anti-TAG-72 mAb-Research Grade |
Clonity |
Monoclonal |
|
Alternate Names recombinant TAG-72 antibody, Anti TAG-72 antibody, tumor associated glycoprotein 72 antibody, anti-mouse TAG-72 antibody, anti-TAG-72 antibody, anti TAG-72 antibody, recombinant TAG-72, TAG-72 antibody, anti-TAG-72 monoclonal antibody, TAG-72 antibodies, TAG-72 recombinant antibody, TAG-72 blocking antibody |
|
Alias |
ABR-214936, pMB125 |
Host |
CHO Cells |
Species |
Human |
Target |
TAG-72 |
Gene ID |
182875 |
Isotype |
Fab-G1 Kappa |
Size |
1mg, 5mg |
Research Area |
Immunology |
Product Description |
Anatumomab mafenatox is a mouse monoclonal antibody, which acts as a tumor-targeted superantigen. |
Application |
ELISA, WB |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
Reference |
1. Jansen L, et al. TAG-72: A comprehensive review of its role as a cancer biomarker and therapeutic target. Cancer Immunology, Immunotherapy. 2020 Oct;69(10):2019-2034. PMID 32633675
2. Carpentier S, et al. The use of TAG-72 as a target for antibody-based therapies in gastrointestinal cancers. Journal of Clinical Oncology. 2019 Sep 20;37(27):2461-2470. PMID 31249773
3. Kumar V, et al. Characterization and therapeutic potential of TAG-72 in cancer treatment. OncoTargets and Therapy. 2019 Aug;12:4567-4582. PMID 31343672
|